Skip to content
Clinical Trials – home
BulgariaBack to Bulgaria

Clinical trials in Sevlievo – page 8

225 clinical trials in Sevlievo, Bulgaria across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Sevlievo at a glance
225
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

225 trials in Sevlievo

Open in trial search

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Hypercholesterolaemia

Not yet recruiting

Effect of laroprovstat/rosuvastatin combination versus laroprovstat, rosuvastatin, and placebo on LDL‑C in hypercholesterolemia patients not previously treated with lipid‑lowering therapy

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Asthma

Not yet recruiting

Asthma in adults: beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide compared with beclometasone dipropionate and formoterol fumarate dihydrate

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Chiesi Farmaceutici S.p.A.

Dermatitis atopic

Not yet recruiting

Testing GIA632 compared to placebo in adults with moderate to severe atopic dermatitis to measure effectiveness and safety

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:GIA632
  • Sponsor:Novartis Pharma AG

Study of telitacicept compared to placebo in adults with moderate to severe systemic lupus erythematosus

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Telitacicept
  • Sponsor:Remegen Co. Ltd.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Metapneumovirus infection

Not yet recruiting

Study on the Effectiveness and Safety of IVX-A12 Vaccine for Preventing Respiratory Infections in Adults Aged 60 and Older

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:IVX-121
  • Sponsor:AstraZeneca AB

Rheumatoid arthritis

Not yet recruiting

Study on the Effectiveness and Safety of Tocilizumab and Methotrexate for Adults with Moderate to Severe Rheumatoid Arthritis

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Dr Reddy's Laboratories Limited

Bronchitis+1

Not yet recruiting

Study of galvokimig versus placebo to assess safety and effectiveness in adults with moderate‑to‑severe chronic obstructive pulmonary disease with chronic bronchitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Galvokimig
  • Sponsor:UCB Biopharma

A Phase 2 Study of LAD603 in Adults with Systemic Lupus Erythematosus and Active Skin Rash

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:LAD603
  • Sponsor:Almirall S.A.

Evaluating the efficacy and safety of CRD-4730 in patients with heart failure with reduced ejection fraction

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:CRD-4730
  • Sponsor:Cardurion Pharmaceuticals Inc.

Other cities in Bulgaria

The busiest research cities in the country

All 52 cities in Bulgaria

Clinical research in Sevlievo

What the registry says about research in the country

01 Respiratory Diseases

Innovative research focusing on respiratory viral infections and chronic conditions, evaluating new vaccines and treatments for improved patient outcomes.

  • RSV and Metapneumovirus Vaccine Studies
  • Influenza Prevention in Elderly
  • Asthma Management Therapies
  • COPD Treatment Innovations

Current trials are testing advanced vaccine formulations and novel therapeutic approaches for both acute and chronic respiratory conditions.

02 Dermatological Conditions

Comprehensive studies examining treatments for various skin disorders, from autoimmune conditions to chronic inflammatory diseases.

  • Plaque Psoriasis Treatments
  • Vitiligo Therapies
  • Atopic Dermatitis Management
  • Chronic Urticaria Solutions

Research focuses on developing targeted therapies for improved symptom management and disease control.

03 Autoimmune Disorders

Groundbreaking research into systemic autoimmune conditions, testing new biological treatments and therapeutic approaches.

  • Lupus (SLE and CLE) Studies
  • Rheumatoid Arthritis Treatments
  • Biosimilar Evaluations

Clinical trials are exploring innovative treatments to address both systemic and organ-specific manifestations of autoimmune diseases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.